SCHEMBL5525906

SCHEMBL5525906

CCOC(=O)c1ccccc1NC=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.64
SENP8 Q96LD8 1/20 0.64
SENP7 Q9BQF6 1/20 0.64
SENP6 Q9GZR1 1/20 0.64
TSHR P16473 4/20 0.62
LMNA P02545 4/20 0.61
ALDH1A1 P00352 7/20 0.60
KDM4E B2RXH2 6/20 0.60
HSD17B10 Q99714 4/20 0.60
KMT2A Q03164 3/20 0.60
CYP1A2 P05177 2/20 0.60
CYP2C19 P33261 2/20 0.60
MAPT P10636 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
HPGD P15428 1/20 0.60
MEN1 O00255 1/20 0.57
RAB9A P51151 1/20 0.57
CDC25B P30305 2/20 0.57
CDC25A P30304 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8115521 0.90 KDM4E (0.56) CASP3SENP8SENP7SENP6TSHR
SCHEMBL5540387 0.88 ALDH1A1 (0.65) CASP3SENP8SENP7SENP6TSHR
SCHEMBL8115706 0.87 KDM4E (0.52) CASP3SENP8SENP7SENP6TSHR
SCHEMBL8106862 0.85 TSHR (0.67) CASP3SENP8SENP7SENP6TSHR
SCHEMBL8123582 0.84 TSHR (0.68) CASP3SENP8SENP7SENP6TSHR
SCHEMBL8116309 0.83 ALDH1A1 (0.66) CASP3SENP8SENP7SENP6TSHR
SCHEMBL8122627 0.83 KDM4E (0.51) CASP3SENP8SENP7SENP6TSHR
SCHEMBL8120935 0.83 TSHR (0.66) CASP3SENP8SENP7SENP6TSHR
SCHEMBL29483352 0.83 KDM4E (0.65) TSHRLMNAALDH1A1KDM4EHSD17B10
SCHEMBL2442267 0.83 KDM4E (0.65) TSHRLMNAALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024182515-A1 AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2024-09-06 WO claimed
US-20240292836-A1 AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE 2024-09-05 US claimed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US claimed
WO-2024182515-A1 AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2024-09-06 WO disclosed
WO-2024182515-A1 AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2024-09-06 WO disclosed
US-20240292836-A1 AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE 2024-09-05 US disclosed
US-20240292836-A1 AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE 2024-09-05 US disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-7241770-B2 Hydronopol derivatives as agonists on human ORL1 receptors SOLVAY PHARMACEUTICALS GMBH (DE) 2007-07-10 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-20050131004-A1 Hydronopol derivatives as agonists on human ORL1 receptors SOLVAY PHARMACEUTICALS GMBH. 2005-06-16 US disclosed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US disclosed
US-6114546-A Aminomethylene derivatives and ultraviolet absorbent comprising thereof CHEMIPRO KASEI KAISHA, LIMITED (JP) 2000-09-05 US disclosed
EP-0950655-A1 AMINOMETHYLENE DERIVATIVES AND ULTRAVIOLET ABSORBER COMPRISING THE SAME CHEMIPRO KASEI KAISHA, LIMITED (JP) 1999-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CASP3 1021/4885SENP8 4471/4885SENP7 4346/4885
US-20050131004-A1 Hydronopol derivatives as agonists on human ORL1 receptors OPRL1, ORMDL3, OGFRL1 CASP3 4379/4885SENP8 4825/4885SENP7 4488/4885
US-20240292836-A1 AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF L3MBTL4, L3MBTL3, L3MBTL1 CASP3 534/4885SENP8 3641/4885SENP7 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.